The emergence of biologic response modifiers and earlier use of immunomodulators for inflammatory bowel disease (IBD) patients have improved outcomes. Durable remissions have been achieved in many IBD patients on these treatments, but the duration of treatment and identifying which patients may stop
Use of biologics in inflammatory bowel disease patients with cirrhosis
โ Scribed by Tanvi Dhere
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 40 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The treatment of Crohn's disease and ulcerative colitis frequently includes potent immunomodulator and biologic therapy to reduce intestinal inflammation, heal fistulae, limit complications, and improve quality of life. These medications may increase susceptibility to and severity of infections, man
## Abstract Inflammatory bowel disease (IBD) affects โ1.4 million people in North America and, because of its typical early age of onset and episodic disease course, IBD patients often undergo numerous imaging studies over the course of their lifetimes. Computed tomography (CT) has become the stand
Patients receiving immunosuppressive therapies may be at increased risk for complications of vaccine preventable diseases, including influenza, varicella, and pneumococcus. However, studies suggest that patients with chronic illness may be inadequately immunized. In part, this is because of a paucit
Endoscopy plays a critical role in the diagnosis and management of inflammatory bowel disease (IBD). This article reviews the utility of endoscopy in the diagnosis of ulcerative colitis (UC) and Crohn's disease (CD), recommendations for cancer surveillance, and the use of newer techniques for the en